18.07.2017 22:30:00
|
BioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET
SAN RAFAEL, Calif., July 18, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, August 2, at 4:30 p.m. ET to discuss second quarter 2017 financial results and provide a general business update.
Dial-in Number
U.S. / Canada Dial-in Number: (866) 502-9859
International Dial-in Number: (574) 990-1362
Conference ID: 41574149
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 41574149
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com.
Contacts:
Investors | Media |
Traci McCarty | Debra Charlesworth |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
(415) 455-7558 | (415) 455-7451 |
View original content with multimedia:http://www.prnewswire.com/news-releases/biomarin-to-host-second-quarter-2017-financial-results-conference-call-and-webcast-on-wednesday-august-2-at-430pm-et-300489741.html
SOURCE BioMarin Pharmaceutical Inc.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Biomarin Pharmaceutical Inc.mehr Nachrichten
Analysen zu Biomarin Pharmaceutical Inc.mehr Analysen
Aktien in diesem Artikel
Biomarin Pharmaceutical Inc. | 62,14 | 0,62% |
|